Claim Missing Document
Check
Articles

Found 2 Documents
Search

Bullous Pemphigoid in a Women with Type 2 Diabetes Mellitus: A Case Report Paul O. Taniowas; Tara S. Kairupan; Marlyn G. Kapantow; Aryani Adji
e-CliniC Vol. 10 No. 1 (2022): e-CliniC
Publisher : Universitas Sam Ratulangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35790/ecl.v10i1.39085

Abstract

Abstract: Bullous Pemphigoid (BP) is an autoimmune disease with subepidermal blisters that are generally minimally itchy to non-itchy. It usually occurs in old age, but sometimes in children and young adults. Clinical presentation shows large, tense-walled blisters on normal or erythematous skin, mostly at the folds, lower abdomen, thighs, but they can appear anywhere. Therapy of BP is aimed to treat skin and mucous lesions as soon as possible and to reduce itchiness, therefore, the quality of life will be improved. The first line therapy is oral and topical corticosteroids, with an initial dose of prednisone 0,75-1mg/kg/day or less. Prednisone tapering should be carried out in accordance with the clinical response and side effects. We reported a 47-year-old female, complained blisters on chest, abdomen, both arms and legs simultaneously. History of uncontrolled diabetes mellitus was present. Skin biopsy revealed subepidermal bullae associated with infiltraton of inflammatory cells, and Nikolsky sign and Asboe-Hansen sign showed negative results. Based on the results, the patient was diagnosed as BP. Prednisone was given 40mg/day with weekly tapering. After two weeks of prednison therapy, the lesions showed great improvement. After six weeks of therapy, the blister formation stopped, and a gradual tapering-off of the corticosteroid dose was recommended according to clinical responses until three months of therapy. The blisters reduced without any side effects. In this case, prednisone showed good result, and complete resolution occurred after six weeks of therapy.Keyword: bullous pemphigoid; diabetes mellitus; prednisone Abstrak: Pemfigoid Bulosa (PB) merupakan penyakit autoimun dengan lepuh subepidermal yang umumnya gatal minimal hingga tidak gatal, lebih sering terjadi pada usia tua, kadang pada anak dan dewasa. Gambaran klinis berupa lepuh besar, dinding tegang di atas kulit normal atau dasar eritematosa. Biasanya ditemukan di lipatan, perut, paha, tetapi bisa muncul di mana saja. Terapi PB bertujuan untuk menyembuhkan lesi kulit dan mukosa dengan cepat dan mengurangi rasa gatal untuk meningkatkan kualitas hidup. Penggunaan kortikosteroid oral dan topikal merupakan lini pertama, dengan dosis awal prednison 0,75-1mg/kg/hari atau kurang. Tapering prednison harus dilakukan sesuai dengan respon klinis dan efek samping. Kami melaporkan kasus seorang wanita, 47 tahun, dengan keluhan lepuh-lepuh di dada, perut, kedua lengan dan kaki muncul bersamaan dengan riwayat diabetes melitus tidak terkontrol. Biopsi kulit dilakukan dengan hasil bula subepidermal disertai infiltrasi sel inflamasi. Nikolsky sign dan Asboe-Hansen sign memberikan hasil negatif. Pasien didiagnosis sebagai PB dan diberikan prednison 40 mg per hari dengan tapering per minggu. Setelah dua minggu terapi prednison, lesi menunjukkan banyak perbaikan. Setelah enam minggu terapi, pembentukan lepuh terhenti, dan dilakukan pengurangan dosis prednison secara bertahap sesuai respons klinis sampai tiga bulan terapi. Lepuh berkurang tanpa efek samping. Pada kasus ini, prednison memberikan hasil yang memuaskan, dan resolusi lengkap tercapai setelah enam minggu terapi.Kata kunci: pemfigoid bulosa; diabetes mellitus; prednison
Male Androgenetic Alopecia Treated with Single Spin Platelet Rich Plasma: A Case Report Anggi Anastasia Ursula Dien; Ferra Olivia Mawu; Aryani Adji; William Yudistha Anggawirya; Paulus Mario Christopher
Eduvest - Journal of Universal Studies Vol. 5 No. 11 (2025): Eduvest - Journal of Universal Studies
Publisher : Green Publisher Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59188/eduvest.v5i11.52334

Abstract

Androgenetic alopecia (AGA) is the most common type of hair loss, causing gradual, progressive miniaturization of hair follicles and shortening of the anagen phase in genetically predisposed men and women, following a distinct pattern. Hair loss usually begins after puberty and is more prevalent in men. This case report details a young male patient with androgenetic alopecia treated with single spin platelet-rich plasma (PRP) therapy combined with topical minoxidil. A 27-year-old Minahasan male experienced hair thinning and loss for 10 years, starting at the middle of his head and spreading outward. Examination showed thinning at the fronto-parietal hairline and vertex, classified as Hamilton-Norwood III vertex. Treatment involved biweekly single spin PRP injections and twice-daily application of 5% topical minoxidil. The PRP was prepared by centrifugation at 3000 rpm for 15 minutes, with up to nine sessions administered. Clinical evaluations through hair pull tests and trichoscopy revealed significant improvement, including increased hair density and changes in follicle diameter in treated areas. By week eighteen, hair density increased markedly, and hair loss diminished without side effects. The patient was highly satisfied with the cosmetic results. This case report indicates that single spin PRP combined with topical minoxidil is an effective, safe, and reliable treatment for male androgenetic alopecia, offering clinical improvement and enhanced hair growth without adverse effects. The simplified PRP protocol provides practical advantages for clinical use, especially in resource-limited settings, and supports growing evidence for PRP as an adjunct therapy for androgenetic alopecia in young Asian patients.